Retrospective analysis of treatment outcomes for extranodal NK/T-cell lymphoma (ENKL), nasal type, stage I-IIE: single i
- PDF / 312,258 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 11 Downloads / 163 Views
ORIGINAL ARTICLE
Retrospective analysis of treatment outcomes for extranodal NK/T-cell lymphoma (ENKL), nasal type, stage I-IIE: single institute experience of combined modality treatment for early localized nasal extranodal NK/T-cell lymphoma (ENKL) Jayoung Lee & Seok-Goo Cho & Su-Mi Chung & Mi Ryeong Ryu & Sung Hwan Kim & Hong-Seok Jang & Byung-Ock Choi
Received: 26 June 2012 / Accepted: 5 November 2012 / Published online: 21 November 2012 # Springer-Verlag Berlin Heidelberg 2012
Abstract Extranodal natural killer/T-cell lymphoma (ENKL) is a very aggressive disease frequently involving the nasal cavity and upper aerodigestive tract. We retrospectively reviewed the treatment outcomes and treatment-associated J. Lee : H.S. Jang : B.O. Choi (*) Department of Radiation Oncology, Seoul St. Mary’s Hospital, The Catholic Medical Center, College of Medicine, The Catholic University of Korea, 137-701, Banpo-dong, 505, Seocho-gu, Seoul, South Korea e-mail: [email protected] S.M. Chung Department of Radiation Oncology, Yeouido St. Mary’s Hospital, The Catholic Medical Center, College of Medicine, The Catholic University of Korea, 150-713, Yeouido-dong 62, Yeongdeungpo-gu, Seoul, South Korea M. R. Ryu Department of Radiation Oncology, Uijeongbu St. Mary’s Hospital, The Catholic Medical Center, College of Medicine, The Catholic University of Korea, 480-717, Geumo-dong 65-1, Uijeongbu-si, Gyeonggi-do, South Korea S. H. Kim Department of Radiation Oncology, St. Vincent’s Hospital, The Catholic Medical Center, College of Medicine, The Catholic University of Korea, 442-723, Ji-dong, Paldal-gu, Suwon-si, Gyeonggi-do, South Korea S.G. Cho Department of Hematology, Seoul St. Mary’s Hospital, The Catholic Medical Center, College of Medicine, The Catholic University of Korea, 137-701, Banpo-dong, 505, Seocho-gu, Seoul, South Korea
complications of the patients with stage I–II early localized ENKL. A total of 24 patients were included. All patients were treated with combined chemoradiotherapy. Three, sixteen, and five patients were initially treated with radiation therapy, chemotherapy, and surgical procedures, respectively. Nine patients underwent hematopoietic stem cell transplantation (HSCT), and four patients administered immunotherapy with pegylated-interferon alpha. The mean observation time was 71.6 months (range, 29.7–183.6 months). Twenty patients achieved complete remission; thus, the overall response rate was 83.3 %. The 5-year overall survival (OS) and relapse-free survival (RFS) rates were 70.3 % and 62.2 %, respectively. In univariate analysis, HSCT was a significant prognostic indicator for OS and RFS. By combining HSCT, the 5-year OS and RFS rates were 100.0 % vs. 52.5 % (p00.018) and 88.9 % vs. 45.7 % (p00.045), respectively. Also, absence of B symptoms was a good prognostic factor for RFS, the 5-year RFS rate, 75.0 % vs. 25.0 % (p00.010), and B symptoms were significant for RFS in multivariate analysis (odds ratio07.4, confidence interval01.6~34.1, p00.011). However, a total of four cases of grade 3 toxicities
Data Loading...
